-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Introduction to IC50 Assay Technology
Author:
InnoModels Biotechnology
Release time:
2024-01-11
InnoModels Biotechnology has always been committed to providing cutting-edge biotechnology solutions to support scientists in the fields of drug discovery and disease research. Among them, the IC50 (half inhibitory concentration) measurement technology is an important innovation in the company's biological research, which provides accurate and reliable data support for key steps in the drug screening and development process.
Definition of IC50
IC50 is the concentration of a drug or compound required to inhibit biological activity by half. It is a commonly used bioactivity assay parameter to assess the inhibitory effect of a compound on biological targets, such as enzyme activity, cell proliferation, etc. The lower the IC50 value, the stronger the inhibitory effect of the compound on the target.
InnoModels Bio's IC50 assay technology
InnoModels's IC50 assay technology provides researchers with a highly accurate, high-throughput assay solution. Below are some of the remarkable features of the technology:
1. Multi-disciplinary applicability:
InnoModels's IC50 assay technology covers a wide range of research areas, including drug discovery, life science research, and more. Whether it is for enzyme, cell, or other biomolecule activity measurement, it can provide reliable IC50 values.
2. High sensitivity:
The company adopts advanced testing instruments and sensitive bioanalytical techniques to ensure that even low concentrations of drugs or compounds can be measured accurately, which improves the credibility of experimental data.
3. Fast and efficient:
InnoModels Bio's IC50 solution is not only highly accurate, but also optimised in terms of experimental cycle time to improve the efficiency of experiments and enable researchers to obtain critical data faster.
4. Customised services:
We offer customised IC50 assay services, designed to meet the specific needs of our customers, ensuring that the unique requirements of different research projects are met to the greatest extent possible.

Application Areas
InnoModels Bio's IC50 assay technology has been widely used in the following areas:
Drug screening and optimisation:
Through IC50 assays, scientists are able to assess the inhibitory effects of potential drug candidates to optimise drug design and development.
Biological Research:
In biological studies, the determination of IC50 values helps researchers gain insight into the function and interaction of biomolecules.
Toxicity Assessment:
Evaluation of the toxicity of compounds in living organisms is an important application of IC50 determination in toxicological studies.
Conclusion
InnoModels Bio's IC50 assay technology is not only an innovation in the field of biological research, but also provides a reliable tool for drug discovery and development. Through continuous technological innovation and service optimisation, the company will continue to play a leading role in the field of IC50 assay, providing scientists with more advanced and efficient research tools to promote the continuous progress of science.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd